1 Study Coverage
1.1 Human Hyperimmune Globulins Product Introduction
1.2 Market by Type
1.2.1 Global Human Hyperimmune Globulins Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Others
1.3 Market by Application
1.3.1 Global Human Hyperimmune Globulins Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Government Institutions
1.3.3 Private Sector
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Human Hyperimmune Globulins Sales Estimates and Forecasts 2017-2028
2.2 Global Human Hyperimmune Globulins Revenue Estimates and Forecasts 2017-2028
2.3 Global Human Hyperimmune Globulins Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Human Hyperimmune Globulins Sales by Region
2.4.1 Global Human Hyperimmune Globulins Sales by Region (2017-2022)
2.4.2 Global Sales Human Hyperimmune Globulins by Region (2023-2028)
2.5 Global Human Hyperimmune Globulins Revenue by Region
2.5.1 Global Human Hyperimmune Globulins Revenue by Region (2017-2022)
2.5.2 Global Human Hyperimmune Globulins Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Human Hyperimmune Globulins Sales by Manufacturers
3.1.1 Global Top Human Hyperimmune Globulins Manufacturers by Sales (2017-2022)
3.1.2 Global Human Hyperimmune Globulins Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Hyperimmune Globulins in 2021
3.2 Global Human Hyperimmune Globulins Revenue by Manufacturers
3.2.1 Global Human Hyperimmune Globulins Revenue by Manufacturers (2017-2022)
3.2.2 Global Human Hyperimmune Globulins Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Human Hyperimmune Globulins Revenue in 2021
3.3 Global Human Hyperimmune Globulins Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Human Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Human Hyperimmune Globulins Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Human Hyperimmune Globulins Sales by Type
4.1.1 Global Human Hyperimmune Globulins Historical Sales by Type (2017-2022)
4.1.2 Global Human Hyperimmune Globulins Forecasted Sales by Type (2023-2028)
4.1.3 Global Human Hyperimmune Globulins Sales Market Share by Type (2017-2028)
4.2 Global Human Hyperimmune Globulins Revenue by Type
4.2.1 Global Human Hyperimmune Globulins Historical Revenue by Type (2017-2022)
4.2.2 Global Human Hyperimmune Globulins Forecasted Revenue by Type (2023-2028)
4.2.3 Global Human Hyperimmune Globulins Revenue Market Share by Type (2017-2028)
4.3 Global Human Hyperimmune Globulins Price by Type
4.3.1 Global Human Hyperimmune Globulins Price by Type (2017-2022)
4.3.2 Global Human Hyperimmune Globulins Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Human Hyperimmune Globulins Sales by Application
5.1.1 Global Human Hyperimmune Globulins Historical Sales by Application (2017-2022)
5.1.2 Global Human Hyperimmune Globulins Forecasted Sales by Application (2023-2028)
5.1.3 Global Human Hyperimmune Globulins Sales Market Share by Application (2017-2028)
5.2 Global Human Hyperimmune Globulins Revenue by Application
5.2.1 Global Human Hyperimmune Globulins Historical Revenue by Application (2017-2022)
5.2.2 Global Human Hyperimmune Globulins Forecasted Revenue by Application (2023-2028)
5.2.3 Global Human Hyperimmune Globulins Revenue Market Share by Application (2017-2028)
5.3 Global Human Hyperimmune Globulins Price by Application
5.3.1 Global Human Hyperimmune Globulins Price by Application (2017-2022)
5.3.2 Global Human Hyperimmune Globulins Price Forecast by Application (2023-2028)
6 North America
6.1 North America Human Hyperimmune Globulins Market Size by Type
6.1.1 North America Human Hyperimmune Globulins Sales by Type (2017-2028)
6.1.2 North America Human Hyperimmune Globulins Revenue by Type (2017-2028)
6.2 North America Human Hyperimmune Globulins Market Size by Application
6.2.1 North America Human Hyperimmune Globulins Sales by Application (2017-2028)
6.2.2 North America Human Hyperimmune Globulins Revenue by Application (2017-2028)
6.3 North America Human Hyperimmune Globulins Market Size by Country
6.3.1 North America Human Hyperimmune Globulins Sales by Country (2017-2028)
6.3.2 North America Human Hyperimmune Globulins Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Human Hyperimmune Globulins Market Size by Type
7.1.1 Europe Human Hyperimmune Globulins Sales by Type (2017-2028)
7.1.2 Europe Human Hyperimmune Globulins Revenue by Type (2017-2028)
7.2 Europe Human Hyperimmune Globulins Market Size by Application
7.2.1 Europe Human Hyperimmune Globulins Sales by Application (2017-2028)
7.2.2 Europe Human Hyperimmune Globulins Revenue by Application (2017-2028)
7.3 Europe Human Hyperimmune Globulins Market Size by Country
7.3.1 Europe Human Hyperimmune Globulins Sales by Country (2017-2028)
7.3.2 Europe Human Hyperimmune Globulins Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Human Hyperimmune Globulins Market Size by Type
8.1.1 Asia Pacific Human Hyperimmune Globulins Sales by Type (2017-2028)
8.1.2 Asia Pacific Human Hyperimmune Globulins Revenue by Type (2017-2028)
8.2 Asia Pacific Human Hyperimmune Globulins Market Size by Application
8.2.1 Asia Pacific Human Hyperimmune Globulins Sales by Application (2017-2028)
8.2.2 Asia Pacific Human Hyperimmune Globulins Revenue by Application (2017-2028)
8.3 Asia Pacific Human Hyperimmune Globulins Market Size by Region
8.3.1 Asia Pacific Human Hyperimmune Globulins Sales by Region (2017-2028)
8.3.2 Asia Pacific Human Hyperimmune Globulins Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Human Hyperimmune Globulins Market Size by Type
9.1.1 Latin America Human Hyperimmune Globulins Sales by Type (2017-2028)
9.1.2 Latin America Human Hyperimmune Globulins Revenue by Type (2017-2028)
9.2 Latin America Human Hyperimmune Globulins Market Size by Application
9.2.1 Latin America Human Hyperimmune Globulins Sales by Application (2017-2028)
9.2.2 Latin America Human Hyperimmune Globulins Revenue by Application (2017-2028)
9.3 Latin America Human Hyperimmune Globulins Market Size by Country
9.3.1 Latin America Human Hyperimmune Globulins Sales by Country (2017-2028)
9.3.2 Latin America Human Hyperimmune Globulins Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Human Hyperimmune Globulins Market Size by Type
10.1.1 Middle East and Africa Human Hyperimmune Globulins Sales by Type (2017-2028)
10.1.2 Middle East and Africa Human Hyperimmune Globulins Revenue by Type (2017-2028)
10.2 Middle East and Africa Human Hyperimmune Globulins Market Size by Application
10.2.1 Middle East and Africa Human Hyperimmune Globulins Sales by Application (2017-2028)
10.2.2 Middle East and Africa Human Hyperimmune Globulins Revenue by Application (2017-2028)
10.3 Middle East and Africa Human Hyperimmune Globulins Market Size by Country
10.3.1 Middle East and Africa Human Hyperimmune Globulins Sales by Country (2017-2028)
10.3.2 Middle East and Africa Human Hyperimmune Globulins Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 CSL Behring
11.1.1 CSL Behring Corporation Information
11.1.2 CSL Behring Overview
11.1.3 CSL Behring Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 CSL Behring Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 CSL Behring Recent Developments
11.2 Grifols
11.2.1 Grifols Corporation Information
11.2.2 Grifols Overview
11.2.3 Grifols Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Grifols Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Grifols Recent Developments
11.3 Biotest
11.3.1 Biotest Corporation Information
11.3.2 Biotest Overview
11.3.3 Biotest Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Biotest Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biotest Recent Developments
11.4 Kedrion
11.4.1 Kedrion Corporation Information
11.4.2 Kedrion Overview
11.4.3 Kedrion Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Kedrion Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Kedrion Recent Developments
11.5 CBPO
11.5.1 CBPO Corporation Information
11.5.2 CBPO Overview
11.5.3 CBPO Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 CBPO Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 CBPO Recent Developments
11.6 Emergent (Cangene)
11.6.1 Emergent (Cangene) Corporation Information
11.6.2 Emergent (Cangene) Overview
11.6.3 Emergent (Cangene) Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Emergent (Cangene) Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Emergent (Cangene) Recent Developments
11.7 Kamada
11.7.1 Kamada Corporation Information
11.7.2 Kamada Overview
11.7.3 Kamada Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Kamada Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Kamada Recent Developments
11.8 CNBG
11.8.1 CNBG Corporation Information
11.8.2 CNBG Overview
11.8.3 CNBG Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 CNBG Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 CNBG Recent Developments
11.9 Hualan Bio
11.9.1 Hualan Bio Corporation Information
11.9.2 Hualan Bio Overview
11.9.3 Hualan Bio Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Hualan Bio Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Hualan Bio Recent Developments
11.10 Shanghai RAAS
11.10.1 Shanghai RAAS Corporation Information
11.10.2 Shanghai RAAS Overview
11.10.3 Shanghai RAAS Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Shanghai RAAS Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shanghai RAAS Recent Developments
11.11 Sichuan Yuanda Shuyang
11.11.1 Sichuan Yuanda Shuyang Corporation Information
11.11.2 Sichuan Yuanda Shuyang Overview
11.11.3 Sichuan Yuanda Shuyang Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Sichuan Yuanda Shuyang Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Sichuan Yuanda Shuyang Recent Developments
11.12 ADMA Biologics
11.12.1 ADMA Biologics Corporation Information
11.12.2 ADMA Biologics Overview
11.12.3 ADMA Biologics Human Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 ADMA Biologics Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 ADMA Biologics Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Human Hyperimmune Globulins Industry Chain Analysis
12.2 Human Hyperimmune Globulins Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Hyperimmune Globulins Production Mode & Process
12.4 Human Hyperimmune Globulins Sales and Marketing
12.4.1 Human Hyperimmune Globulins Sales Channels
12.4.2 Human Hyperimmune Globulins Distributors
12.5 Human Hyperimmune Globulins Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Human Hyperimmune Globulins Industry Trends
13.2 Human Hyperimmune Globulins Market Drivers
13.3 Human Hyperimmune Globulins Market Challenges
13.4 Human Hyperimmune Globulins Market Restraints
14 Key Findings in The Global Human Hyperimmune Globulins Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Human Hyperimmune Globulins Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Hepatitis B Immunoglobulins
Table 3. Major Manufacturers of Rabies Immunoglobulins
Table 4. Major Manufacturers of Tetanus Immunoglobulins
Table 5. Major Manufacturers of Others
Table 6. Global Human Hyperimmune Globulins Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Human Hyperimmune Globulins Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Human Hyperimmune Globulins Sales by Region (2017-2022) & (K Units)
Table 9. Global Human Hyperimmune Globulins Sales Market Share by Region (2017-2022)
Table 10. Global Human Hyperimmune Globulins Sales by Region (2023-2028) & (K Units)
Table 11. Global Human Hyperimmune Globulins Sales Market Share by Region (2023-2028)
Table 12. Global Human Hyperimmune Globulins Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Human Hyperimmune Globulins Revenue Market Share by Region (2017-2022)
Table 14. Global Human Hyperimmune Globulins Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Human Hyperimmune Globulins Revenue Market Share by Region (2023-2028)
Table 16. Global Human Hyperimmune Globulins Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global Human Hyperimmune Globulins Sales Share by Manufacturers (2017-2022)
Table 18. Global Human Hyperimmune Globulins Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Human Hyperimmune Globulins Revenue Share by Manufacturers (2017-2022)
Table 20. Human Hyperimmune Globulins Price by Manufacturers (2017-2022) &(US$/Unit)
Table 21. Global Human Hyperimmune Globulins Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Human Hyperimmune Globulins by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Hyperimmune Globulins as of 2021)
Table 23. Human Hyperimmune Globulins Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Human Hyperimmune Globulins Product Offered
Table 25. Date of Manufacturers Enter into Human Hyperimmune Globulins Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Human Hyperimmune Globulins Sales by Type (2017-2022) & (K Units)
Table 28. Global Human Hyperimmune Globulins Sales by Type (2023-2028) & (K Units)
Table 29. Global Human Hyperimmune Globulins Sales Share by Type (2017-2022)
Table 30. Global Human Hyperimmune Globulins Sales Share by Type (2023-2028)
Table 31. Global Human Hyperimmune Globulins Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Human Hyperimmune Globulins Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Human Hyperimmune Globulins Revenue Share by Type (2017-2022)
Table 34. Global Human Hyperimmune Globulins Revenue Share by Type (2023-2028)
Table 35. Human Hyperimmune Globulins Price by Type (2017-2022) & (US$/Unit)
Table 36. Global Human Hyperimmune Globulins Price Forecast by Type (2023-2028) & (US$/Unit)
Table 37. Global Human Hyperimmune Globulins Sales by Application (2017-2022) & (K Units)
Table 38. Global Human Hyperimmune Globulins Sales by Application (2023-2028) & (K Units)
Table 39. Global Human Hyperimmune Globulins Sales Share by Application (2017-2022)
Table 40. Global Human Hyperimmune Globulins Sales Share by Application (2023-2028)
Table 41. Global Human Hyperimmune Globulins Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Human Hyperimmune Globulins Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Human Hyperimmune Globulins Revenue Share by Application (2017-2022)
Table 44. Global Human Hyperimmune Globulins Revenue Share by Application (2023-2028)
Table 45. Human Hyperimmune Globulins Price by Application (2017-2022) & (US$/Unit)
Table 46. Global Human Hyperimmune Globulins Price Forecast by Application (2023-2028) & (US$/Unit)
Table 47. North America Human Hyperimmune Globulins Sales by Type (2017-2022) & (K Units)
Table 48. North America Human Hyperimmune Globulins Sales by Type (2023-2028) & (K Units)
Table 49. North America Human Hyperimmune Globulins Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Human Hyperimmune Globulins Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Human Hyperimmune Globulins Sales by Application (2017-2022) & (K Units)
Table 52. North America Human Hyperimmune Globulins Sales by Application (2023-2028) & (K Units)
Table 53. North America Human Hyperimmune Globulins Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Human Hyperimmune Globulins Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Human Hyperimmune Globulins Sales by Country (2017-2022) & (K Units)
Table 56. North America Human Hyperimmune Globulins Sales by Country (2023-2028) & (K Units)
Table 57. North America Human Hyperimmune Globulins Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Human Hyperimmune Globulins Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Human Hyperimmune Globulins Sales by Type (2017-2022) & (K Units)
Table 60. Europe Human Hyperimmune Globulins Sales by Type (2023-2028) & (K Units)
Table 61. Europe Human Hyperimmune Globulins Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Human Hyperimmune Globulins Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Human Hyperimmune Globulins Sales by Application (2017-2022) & (K Units)
Table 64. Europe Human Hyperimmune Globulins Sales by Application (2023-2028) & (K Units)
Table 65. Europe Human Hyperimmune Globulins Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Human Hyperimmune Globulins Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Human Hyperimmune Globulins Sales by Country (2017-2022) & (K Units)
Table 68. Europe Human Hyperimmune Globulins Sales by Country (2023-2028) & (K Units)
Table 69. Europe Human Hyperimmune Globulins Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Human Hyperimmune Globulins Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Human Hyperimmune Globulins Sales by Type (2017-2022) & (K Units)
Table 72. Asia Pacific Human Hyperimmune Globulins Sales by Type (2023-2028) & (K Units)
Table 73. Asia Pacific Human Hyperimmune Globulins Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Human Hyperimmune Globulins Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Human Hyperimmune Globulins Sales by Application (2017-2022) & (K Units)
Table 76. Asia Pacific Human Hyperimmune Globulins Sales by Application (2023-2028) & (K Units)
Table 77. Asia Pacific Human Hyperimmune Globulins Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Human Hyperimmune Globulins Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Human Hyperimmune Globulins Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific Human Hyperimmune Globulins Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific Human Hyperimmune Globulins Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Human Hyperimmune Globulins Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Human Hyperimmune Globulins Sales by Type (2017-2022) & (K Units)
Table 84. Latin America Human Hyperimmune Globulins Sales by Type (2023-2028) & (K Units)
Table 85. Latin America Human Hyperimmune Globulins Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Human Hyperimmune Globulins Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Human Hyperimmune Globulins Sales by Application (2017-2022) & (K Units)
Table 88. Latin America Human Hyperimmune Globulins Sales by Application (2023-2028) & (K Units)
Table 89. Latin America Human Hyperimmune Globulins Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Human Hyperimmune Globulins Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Human Hyperimmune Globulins Sales by Country (2017-2022) & (K Units)
Table 92. Latin America Human Hyperimmune Globulins Sales by Country (2023-2028) & (K Units)
Table 93. Latin America Human Hyperimmune Globulins Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Human Hyperimmune Globulins Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Human Hyperimmune Globulins Sales by Type (2017-2022) & (K Units)
Table 96. Middle East and Africa Human Hyperimmune Globulins Sales by Type (2023-2028) & (K Units)
Table 97. Middle East and Africa Human Hyperimmune Globulins Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Human Hyperimmune Globulins Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Human Hyperimmune Globulins Sales by Application (2017-2022) & (K Units)
Table 100. Middle East and Africa Human Hyperimmune Globulins Sales by Application (2023-2028) & (K Units)
Table 101. Middle East and Africa Human Hyperimmune Globulins Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Human Hyperimmune Globulins Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Human Hyperimmune Globulins Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa Human Hyperimmune Globulins Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa Human Hyperimmune Globulins Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Human Hyperimmune Globulins Revenue by Country (2023-2028) & (US$ Million)
Table 107. CSL Behring Corporation Information
Table 108. CSL Behring Description and Major Businesses
Table 109. CSL Behring Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. CSL Behring Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. CSL Behring Recent Developments
Table 112. Grifols Corporation Information
Table 113. Grifols Description and Major Businesses
Table 114. Grifols Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. Grifols Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Grifols Recent Developments
Table 117. Biotest Corporation Information
Table 118. Biotest Description and Major Businesses
Table 119. Biotest Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. Biotest Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Biotest Recent Developments
Table 122. Kedrion Corporation Information
Table 123. Kedrion Description and Major Businesses
Table 124. Kedrion Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. Kedrion Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Kedrion Recent Developments
Table 127. CBPO Corporation Information
Table 128. CBPO Description and Major Businesses
Table 129. CBPO Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. CBPO Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. CBPO Recent Developments
Table 132. Emergent (Cangene) Corporation Information
Table 133. Emergent (Cangene) Description and Major Businesses
Table 134. Emergent (Cangene) Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. Emergent (Cangene) Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Emergent (Cangene) Recent Developments
Table 137. Kamada Corporation Information
Table 138. Kamada Description and Major Businesses
Table 139. Kamada Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 140. Kamada Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Kamada Recent Developments
Table 142. CNBG Corporation Information
Table 143. CNBG Description and Major Businesses
Table 144. CNBG Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 145. CNBG Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. CNBG Recent Developments
Table 147. Hualan Bio Corporation Information
Table 148. Hualan Bio Description and Major Businesses
Table 149. Hualan Bio Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 150. Hualan Bio Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Hualan Bio Recent Developments
Table 152. Shanghai RAAS Corporation Information
Table 153. Shanghai RAAS Description and Major Businesses
Table 154. Shanghai RAAS Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 155. Shanghai RAAS Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Shanghai RAAS Recent Developments
Table 157. Sichuan Yuanda Shuyang Corporation Information
Table 158. Sichuan Yuanda Shuyang Description and Major Businesses
Table 159. Sichuan Yuanda Shuyang Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 160. Sichuan Yuanda Shuyang Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Sichuan Yuanda Shuyang Recent Developments
Table 162. ADMA Biologics Corporation Information
Table 163. ADMA Biologics Description and Major Businesses
Table 164. ADMA Biologics Human Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 165. ADMA Biologics Human Hyperimmune Globulins Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. ADMA Biologics Recent Developments
Table 167. Key Raw Materials Lists
Table 168. Raw Materials Key Suppliers Lists
Table 169. Human Hyperimmune Globulins Distributors List
Table 170. Human Hyperimmune Globulins Customers List
Table 171. Human Hyperimmune Globulins Market Trends
Table 172. Human Hyperimmune Globulins Market Drivers
Table 173. Human Hyperimmune Globulins Market Challenges
Table 174. Human Hyperimmune Globulins Market Restraints
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Hyperimmune Globulins Product Picture
Figure 3. Global Human Hyperimmune Globulins Market Share by Type in 2021 & 2028
Figure 3. Hepatitis B Immunoglobulins Product Picture
Figure 4. Rabies Immunoglobulins Product Picture
Figure 5. Tetanus Immunoglobulins Product Picture
Figure 6. Others Product Picture
Figure 7. Global Human Hyperimmune Globulins Market Share by Application in 2021 & 2028
Figure 8. Government Institutions
Figure 9. Private Sector
Figure 10. Others
Figure 11. Human Hyperimmune Globulins Report Years Considered
Figure 12. Global Human Hyperimmune Globulins Sales 2017-2028 (K Units)
Figure 13. Global Human Hyperimmune Globulins Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Human Hyperimmune Globulins Revenue 2017-2028 (US$ Million)
Figure 15. Global Human Hyperimmune Globulins Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Human Hyperimmune Globulins Sales Market Share by Region (2017-2022)
Figure 17. Global Human Hyperimmune Globulins Sales Market Share by Region (2023-2028)
Figure 18. North America Human Hyperimmune Globulins Sales YoY (2017-2028) & (K Units)
Figure 19. North America Human Hyperimmune Globulins Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Human Hyperimmune Globulins Sales YoY (2017-2028) & (K Units)
Figure 21. Europe Human Hyperimmune Globulins Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Asia-Pacific Human Hyperimmune Globulins Sales YoY (2017-2028) & (K Units)
Figure 23. Asia-Pacific Human Hyperimmune Globulins Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Latin America Human Hyperimmune Globulins Sales YoY (2017-2028) & (K Units)
Figure 25. Latin America Human Hyperimmune Globulins Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Middle East & Africa Human Hyperimmune Globulins Sales YoY (2017-2028) & (K Units)
Figure 27. Middle East & Africa Human Hyperimmune Globulins Revenue YoY (2017-2028) & (US$ Million)
Figure 28. The Human Hyperimmune Globulins Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 29. The Top 5 and 10 Largest Manufacturers of Human Hyperimmune Globulins in the World: Market Share by Human Hyperimmune Globulins Revenue in 2021
Figure 30. Global Human Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 31. Global Human Hyperimmune Globulins Sales Market Share by Type (2017-2028)
Figure 32. Global Human Hyperimmune Globulins Revenue Market Share by Type (2017-2028)
Figure 33. Global Human Hyperimmune Globulins Sales Market Share by Application (2017-2028)
Figure 34. Global Human Hyperimmune Globulins Revenue Market Share by Application (2017-2028)
Figure 35. North America Human Hyperimmune Globulins Sales Market Share by Type (2017-2028)
Figure 36. North America Human Hyperimmune Globulins Revenue Market Share by Type (2017-2028)
Figure 37. North America Human Hyperimmune Globulins Sales Market Share by Application (2017-2028)
Figure 38. North America Human Hyperimmune Globulins Revenue Market Share by Application (2017-2028)
Figure 39. North America Human Hyperimmune Globulins Sales Share by Country (2017-2028)
Figure 40. North America Human Hyperimmune Globulins Revenue Share by Country (2017-2028)
Figure 41. United States Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 42. Canada Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 43. Europe Human Hyperimmune Globulins Sales Market Share by Type (2017-2028)
Figure 44. Europe Human Hyperimmune Globulins Revenue Market Share by Type (2017-2028)
Figure 45. Europe Human Hyperimmune Globulins Sales Market Share by Application (2017-2028)
Figure 46. Europe Human Hyperimmune Globulins Revenue Market Share by Application (2017-2028)
Figure 47. Europe Human Hyperimmune Globulins Sales Share by Country (2017-2028)
Figure 48. Europe Human Hyperimmune Globulins Revenue Share by Country (2017-2028)
Figure 49. Germany Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 50. France Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 51. U.K. Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 52. Italy Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 53. Russia Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 54. Asia Pacific Human Hyperimmune Globulins Sales Market Share by Type (2017-2028)
Figure 55. Asia Pacific Human Hyperimmune Globulins Revenue Market Share by Type (2017-2028)
Figure 56. Asia Pacific Human Hyperimmune Globulins Sales Market Share by Application (2017-2028)
Figure 57. Asia Pacific Human Hyperimmune Globulins Revenue Market Share by Application (2017-2028)
Figure 58. Asia Pacific Human Hyperimmune Globulins Sales Share by Region (2017-2028)
Figure 59. Asia Pacific Human Hyperimmune Globulins Revenue Share by Region (2017-2028)
Figure 60. China Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 61. Japan Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 62. South Korea Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 63. India Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 64. Australia Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 65. China Taiwan Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 66. Indonesia Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 67. Thailand Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 68. Malaysia Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 69. Latin America Human Hyperimmune Globulins Sales Market Share by Type (2017-2028)
Figure 70. Latin America Human Hyperimmune Globulins Revenue Market Share by Type (2017-2028)
Figure 71. Latin America Human Hyperimmune Globulins Sales Market Share by Application (2017-2028)
Figure 72. Latin America Human Hyperimmune Globulins Revenue Market Share by Application (2017-2028)
Figure 73. Latin America Human Hyperimmune Globulins Sales Share by Country (2017-2028)
Figure 74. Latin America Human Hyperimmune Globulins Revenue Share by Country (2017-2028)
Figure 75. Mexico Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 76. Brazil Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 77. Argentina Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Human Hyperimmune Globulins Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Human Hyperimmune Globulins Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Human Hyperimmune Globulins Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Human Hyperimmune Globulins Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Human Hyperimmune Globulins Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Human Hyperimmune Globulins Revenue Share by Country (2017-2028)
Figure 84. Turkey Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Human Hyperimmune Globulins Revenue (2017-2028) & (US$ Million)
Figure 87. Human Hyperimmune Globulins Value Chain
Figure 88. Human Hyperimmune Globulins Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed
